News & Updates

The combination of nivolumab 1 mg/kg (NIVO1) and ipilimumab 3 mg/kg (IPI3) every 3 weeks followed by NIVO 240 mg every 2 weeks in the second-line setting continues to confer durable response and overall survival (OS) benefit in patients with advanced hepatocellular carcinoma (aHCC), according to 5-year data from the CheckMate 040* trial presented at ESMO GI 2022.

The benefit of adding durvalumab to gemcitabine plus cisplatin chemotherapy in patients with advanced biliary tract cancer (BTC) was consistent regardless of primary tumour location, according to a subgroup analysis of the phase III TOPAZ-1 study presented at ESMO GI 2022.

The combination of stereotactic radiosurgery (SRS) with targeted chemotherapy treatments appears to improve disease outcomes in cancer patients with brain metastasis, reports a recent study.

Older patients, men, and those belonging to lower socioeconomic groups tend to receive less hospital-based specialized palliative care (SPC), reports a recent study. Such a pattern indicates potential under-treatment in these populations.